IVVD Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

14.22M

+2.86%

-0.087

-41.67%

16.95M

+49.95%

-0.130

-7.14%

17.85M

+51.45%

-0.135

+12.5%

Estimates Revision

The market is revising Upward the revenue expectations for Invivyd, Inc. (IVVD) for FY2025, with the revenue forecasts being adjusted by 0.25% over the past three months. During the same period, the stock price has changed by 33.33%.

Revenue Estimates for FY2025

Revise Upward

+0.25%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-10.23%

In Past 3 Month

Stock Price

Go Up

+33.33%

In Past 3 Month

3 Analyst Rating

Wall Street analysts forecast IVVD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IVVD is 10.00 USD with a low forecast of 10.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

10.00

Averages

10.00

High

10.00

Current: 0.000

Low

10.00

Averages

10.00

High

10.00

Boral Capital

D. Boral

Buy

Hold

downgrade

2025-11-25

Reason

Boral Capital

D. Boral

Price Target

2025-11-25

downgrade

Buy

Hold

Reason

D. Boral Capital downgraded Invivyd to Hold from Buy with no price target after the company announced the nomination of its next-generation RSV antibody VBY329 with IND readiness targeted for the second half of 2026 and concurrently strengthened its capital position through a $125M equity offering. With the fundraise anticipated in the firm's prior modeling, the transaction does not alter its valuation framework, but with its previous $2 price target achieved, it now shifts to Hold as the shares more fully reflect pipeline and balance sheet expectations.

H.C. Wainwright

Patrick Trucchio

Buy

maintain

$5 -> $10

2025-10-31

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$5 -> $10

2025-10-31

maintain

Buy

Reason

H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Invivyd to $10 from $5 and keeps a Buy rating on the shares after the company unveiled the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody for COVID-19 prevention. The firm views the REVOLUTION launch as a "meaningful inflection point" that strengthens Invivyd's regulatory and commercial narrative.

H.C. Wainwright

Buy

downgrade

$10 -> $5

2025-05-28

Reason

H.C. Wainwright

Price Target

$10 -> $5

2025-05-28

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Invivyd to $5 from $10 and keeps a Buy rating on the shares following the Q1 revenue shortfall. Invivyd's platform continues to evolve beyond COVID-19, with early signs of operational stabilization and pipeline expansion emerging in Q2, the analyst tells investors in a research note. The firm believes the company is transitioning from a single-asset COVID-19 story to a broader antibody-based infectious disease platform. It believes Invivyd has "multiple potential catalysts for near-term value creation."

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$10

2025-03-26

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$10

2025-03-26

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-20

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-20

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-05

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-05

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Invivyd Inc (IVVD.O) is -5.13, compared to its 5-year average forward P/E of -1.91. For a more detailed relative valuation and DCF analysis to assess Invivyd Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.91

Current PE

-5.13

Overvalued PE

4.39

Undervalued PE

-8.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.07

Current EV/EBITDA

-6.54

Overvalued EV/EBITDA

5.12

Undervalued EV/EBITDA

-7.26

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

12.10

Current PS

8.59

Overvalued PS

45.44

Undervalued PS

-21.24

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 433.14% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

IVVD News & Events

Events Timeline

No data

News

9.5

01-08Globenewswire

PinnedInvivyd Reports Q4 2025 Revenue of $17.2M, Up 25% Year-over-Year

9.0

2025-12-23Globenewswire

Invivyd Receives FDA Fast Track Designation for VYD2311 Vaccine

9.0

2025-12-23Globenewswire

Invivyd Initiates Phase 3 DECLARATION Trial for VYD2311 with 1770 Participants

People Also Watch

Frequently Asked Questions

What is Invivyd Inc (IVVD) stock price today?

The current price of IVVD is 2.52 USD — it has increased 0.4 % in the last trading day.

What is Invivyd Inc (IVVD)'s business?

Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.

What is the price predicton of IVVD Stock?

What is Invivyd Inc (IVVD)'s revenue for the last quarter?

Invivyd Inc revenue for the last quarter amounts to 13.13M USD, increased 41.17 % YoY.

What is Invivyd Inc (IVVD)'s earnings per share (EPS) for the last quarter?

Invivyd Inc. EPS for the last quarter amounts to -0.06 USD, decreased -88.24 % YoY.

What changes have occurred in the market's expectations for Invivyd Inc (IVVD)'s fundamentals?

How many employees does Invivyd Inc (IVVD). have?

Invivyd Inc (IVVD) has 99 emplpoyees as of January 10 2026.

What is Invivyd Inc (IVVD) market cap?

Today IVVD has the market capitalization of 710.61M USD.